RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Miradon
Synonyms :
anisindione
Class :
Anticoagulants, Cardiovascular
Brand Name :
Miradon
Synonyms :
anisindione
Class :
Anticoagulants, Cardiovascular
Dosage Forms & Strengths
Tablet
50 mg
Take initial dose of 300 mg, 200 mg and 100 mg orally on first, second and third day respectively
Not determined
Refer to adult dosing
desirubin: they may increase the anticoagulant effect of anticoagulants
due to anticoagulant properties of taheebo, other anticoagulant use is contraindicated
use caution when bladderwrack is used in combination with anticoagulant medication due to antiplatelet action
bloodroot along with anticoagulant medications will result in bleeding and bruising
when combined, may increase anticoagulation
edoxaban increases the effect of anticoagulants
hemin increases the effect of anticoagulants
it increases the toxicity of anticoagulants
anticoagulants increase the toxicity of omacetaxine
vorapaxar increases the toxicity of anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased thrombogenic effect when combined with anti- coagulant inhibitor complex
urokinase: they may increase the anticoagulant effect of anticoagulants
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
antiplatelet agents increase the effect of anticoagulants
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
When bacampicillin combines with anisindione, there may be increased risk of bleeding in liver and hepatic impairment and mostly in elderly patients.
When penicillin G benzathine combines with anisindione, the increased risk of bleeding is seen in renal or liver impairment and elderly patients.
when both drugs are combined, there may be an increased risk or severity of adverse effects
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with anisindione it decreases the effects of action of the drug and results in renal and liver impairment
amoxicillin and clavulanate potassium
when amoxicillin combines with anisindione it decreases the effects of action of the drug and results in renal and liver impairment
omeprazole amoxicillin and clarithromycin
when both drugs are combined, there may be a decreased effect of the drug's action by decreasing renal clearance
when both drugs are combined, there may be a decreased effect of the drug's action by decreasing renal clearance
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
bromeperidol increases the toxicity of anticoagulants
it increases the effect of anticoagulants
may enhance the nephrotoxic effect of salicylates
may have an increased adverse effect when combined with anticoagulants
may have an increased adverse effect when combined with anticoagulants
may have an increased adverse effect when combined with anticoagulants
may have an increased adverse effect when combined with ibritumomab tiuxetan
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deoxycholic acid
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may have an increasingly adverse effect when combined with nintedanib
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with obinutuzumab
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may reduce the anticoagulant effect
may reduce the anticoagulant effect
choline magnesium trisalicylate
may enhance the anticoagulant effect
may decrease the therapeutic effect of factor X
may have an increasingly adverse effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the anticoagulant effects of each other when combined
may increase the anticoagulant effect when combined
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may increase the risk of haemorrhage with oral anticoagulants
may increase the risk of haemorrhage with oral anticoagulants
may increase the risk of haemorrhage with oral anticoagulants
eplerenone: they may increase the anticoagulant effect of anticoagulants
vitamin E: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
ceritinib: they may increase the anticoagulant effect of anticoagulants
The anticoagulant effects of ancord may be enhanced when administered concomitantly with other anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
ispaghula husk may lower or decrease the rate of GI absorption of coumarin derivatives
caplacizumab has the potential to increase the anticoagulant activity of other anticoagulants
Actions and Spectrum
anisindione exerts its anticoagulant effect by inhibiting the production of vitamin K-dependent clotting factors in the liver.
Frequency not defined
Dizziness
Difficulty breathing
Swelling of your face, lips, tongue
Limited range of motion
Pain
Nausea
Diarrhea
Fever
Limping
Joint pain
Pain or discomfort
Hives
Skin irritation
Hair loss
Difficulty reaching overhead
Mouth sores
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: N/A
Lactation: Excretion into human milk is known
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
anisindione inhibits the enzyme vitamin K epoxide reductase (VKOR), which is responsible for the recycling of vitamin K to its active form. By inhibiting VKOR, anisindione reduces the production of these vitamin K-dependent factors, leading to an anticoagulant effect.
Pharmacodynamics
anisindione has a delayed onset of action due to its need to interfere with the synthesis of existing clotting factors.
Pharmacokinetics
Absorption
anisindione is absorbed from the gastrointestinal tract.
Distribution
anisindione is distributed throughout the body via the bloodstream. action.
Metabolism
anisindione undergoes extensive metabolism in the liver.
Elimination and excretion
anisindione is eliminated from the body primarily through the urine.
Administration
anisindione is typically administered orally and available in tablet form.
Patient information leaflet
Generic Name: anisindione
Why do we use anisindione?
anisindione is used for the prevention and treatment of various thromboembolic conditions.
anisindione was used to prevent and treat Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
